MiNK Therapeutics, Inc.
General ticker "INKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $42.3M (TTM average)
MiNK Therapeutics, Inc. follows the US Stock Market performance with the rate: 23.8%.
Estimated limits based on current volatility of 4.1%: low 10.80$, high 11.72$
Factors to consider:
- Total employees count: 23 (-25.8%) as of 2024
- Top business risk factors: Operational and conduct risks, Product candidate success, Clinical trial delays, Labor/talent shortage/retention, Third-party risks
- Current price 16.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.68$, 10.58$]
- 2025-12-31 to 2026-12-31 estimated range: [3.23$, 9.32$]
Financial Metrics affecting the INKT estimates:
- Positive: with PPE of -1.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -46.53 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.66
- Negative: Shareholder equity ratio, % of -342.36 <= 18.93
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term INKT quotes
Long-term INKT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $30.95MM | $22.92MM | $11.29MM |
| Operating Income | $-30.95MM | $-22.92MM | $-11.29MM |
| Non-Operating Income | $2.96MM | $0.46MM | $0.50MM |
| R&D Expense | $23.12MM | $15.49MM | $6.34MM |
| Income(Loss) | $-27.99MM | $-22.46MM | $-10.78MM |
| Profit(Loss)* | $-27.99MM | $-22.46MM | $-10.78MM |
| Stockholders Equity | $-0.40MM | $-18.06MM | $-19.59MM |
| Assets | $21.47MM | $4.55MM | $5.72MM |
| Operating Cash Flow | $-18.87MM | $-15.76MM | $-9.56MM |
| Capital expenditure | $0.25MM | $0.07MM | $0.00MM |
| Investing Cash Flow | $-0.25MM | $-0.07MM | $0.00MM |
| Financing Cash Flow | $-0.16MM | $-0.41MM | $10.82MM |
| Earnings Per Share** | $-8.31 | $-6.54 | $-2.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.